FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893948512> ?p ?o ?g. }

• W2893948512 endingPage "155s" @default.
• W2893948512 startingPage "155s" @default.
• W2893948512 abstract "Background and context: Several studies showed that the use of the recombinant monoclonal antibody trastuzumab, in addition to adjuvant chemotherapy, for breast cancer with overexpression of the HER-2 protein or amplification of the HER-2/neu gene reduced the risk of recurrence by 50% in women irrespective of nodal status. In Nigeria, breast cancer is the leading and the most common cancer in women. A trastuzumab brand known as Herceptin is the popular brand usually prescribed by the oncologist in Nigeria. Once a histopathology/immune-chemistry result shows HER-2 positive and oncologist informs that patient of the diagnosis being HER-2 positive; most patients emotionally breaks down due to cost of the drugs. In Nigeria, as at 2015 the cost of herceptin 455mg was N650,000 ($1857). As at June 2016 that same drug increased in cost to N1,100,000 ($3142) due to the unstable exchange rate in Nigeria. In Nigeria 90% of patients pay-out of pocket for treatment and drugs as the health insurance system in my country does not cover chemotherapy drugs. Several cancer patients with HER-2 patients face serious financial challenges in Nigeria, as so many experience spread of the cancer to vital organ when they are unable to get finance to purchase the life-saving drug for their HER-2 positive breast cancer subtype. Aim: To understand the burden of HER-2 diagnosis in Nigeria and stimulate advocacy for the reduction of the cost of Herceptin in Nigeria and other sub-Saharan Africa where finance is a serious impediment to accessing medical care. Strategy/Tactics: The study will present case studies of three Nigerian women who were diagnosed of HER-2. Interview was used as a method of data collection, informed consent were also completed by the patients before the interview. Program/Policy process: Our study reveals that there is a need to engage the federal and state governments, corporate organizations, insurance schemes and most importantly pharmaceutical companies to reduce cost of cancer drugs and particularly Herceptin. HER-2 breast cancer patients need to lead the advocacy for reduction in cost of drug at all levels. Outcomes: Our qualitative findings reveal that caregivers are mostly affected by the cost of drugs such as Herceptin. In some cases caregivers, sell valuables, take loan and go public to raise funds for the cancer drugs. What was learned: Most HER-2 positive breast cancer patient could not afford Herceptin and some waited for several months to raise funds, which is probably a factor in metastasis and low-survival." @default.
• W2893948512 created "2018-10-05" @default.
• W2893948512 creator A5020059465 @default.
• W2893948512 creator A5025110800 @default.
• W2893948512 creator A5027450718 @default.
• W2893948512 creator A5029140469 @default.
• W2893948512 creator A5047714021 @default.
• W2893948512 creator A5054503758 @default.
• W2893948512 creator A5066316908 @default.
• W2893948512 creator A5074672765 @default.
• W2893948512 creator A5074754108 @default.
• W2893948512 creator A5075886668 @default.
• W2893948512 creator A5086964873 @default.
• W2893948512 creator A5090680730 @default.
• W2893948512 creator A5091771325 @default.
• W2893948512 date "2018-10-01" @default.
• W2893948512 modified "2023-10-11" @default.
• W2893948512 title "The Burden of HER-2 Positive Patients in Sub-Saharan Africa: A Caregiver Perspective" @default.
• W2893948512 doi "https://doi.org/10.1200/jgo.18.73500" @default.
• W2893948512 hasPublicationYear "2018" @default.
• W2893948512 type Work @default.
• W2893948512 sameAs 2893948512 @default.
• W2893948512 citedByCount "1" @default.
• W2893948512 countsByYear W28939485122023 @default.
• W2893948512 crossrefType "journal-article" @default.
• W2893948512 hasAuthorship W2893948512A5020059465 @default.
• W2893948512 hasAuthorship W2893948512A5025110800 @default.
• W2893948512 hasAuthorship W2893948512A5027450718 @default.
• W2893948512 hasAuthorship W2893948512A5029140469 @default.
• W2893948512 hasAuthorship W2893948512A5047714021 @default.
• W2893948512 hasAuthorship W2893948512A5054503758 @default.
• W2893948512 hasAuthorship W2893948512A5066316908 @default.
• W2893948512 hasAuthorship W2893948512A5074672765 @default.
• W2893948512 hasAuthorship W2893948512A5074754108 @default.
• W2893948512 hasAuthorship W2893948512A5075886668 @default.
• W2893948512 hasAuthorship W2893948512A5086964873 @default.
• W2893948512 hasAuthorship W2893948512A5090680730 @default.
• W2893948512 hasAuthorship W2893948512A5091771325 @default.
• W2893948512 hasBestOaLocation W28939485121 @default.
• W2893948512 hasConcept C121608353 @default.
• W2893948512 hasConcept C126322002 @default.
• W2893948512 hasConcept C143998085 @default.
• W2893948512 hasConcept C151730666 @default.
• W2893948512 hasConcept C2777329042 @default.
• W2893948512 hasConcept C2779343474 @default.
• W2893948512 hasConcept C2779786085 @default.
• W2893948512 hasConcept C512399662 @default.
• W2893948512 hasConcept C530470458 @default.
• W2893948512 hasConcept C71924100 @default.
• W2893948512 hasConcept C86803240 @default.
• W2893948512 hasConceptScore W2893948512C121608353 @default.
• W2893948512 hasConceptScore W2893948512C126322002 @default.
• W2893948512 hasConceptScore W2893948512C143998085 @default.
• W2893948512 hasConceptScore W2893948512C151730666 @default.
• W2893948512 hasConceptScore W2893948512C2777329042 @default.
• W2893948512 hasConceptScore W2893948512C2779343474 @default.
• W2893948512 hasConceptScore W2893948512C2779786085 @default.
• W2893948512 hasConceptScore W2893948512C512399662 @default.
• W2893948512 hasConceptScore W2893948512C530470458 @default.
• W2893948512 hasConceptScore W2893948512C71924100 @default.
• W2893948512 hasConceptScore W2893948512C86803240 @default.
• W2893948512 hasIssue "Supplement 2" @default.
• W2893948512 hasLocation W28939485121 @default.
• W2893948512 hasOpenAccess W2893948512 @default.
• W2893948512 hasPrimaryLocation W28939485121 @default.
• W2893948512 hasRelatedWork W1964065629 @default.
• W2893948512 hasRelatedWork W1967506091 @default.
• W2893948512 hasRelatedWork W2166148619 @default.
• W2893948512 hasRelatedWork W2167587342 @default.
• W2893948512 hasRelatedWork W2262572336 @default.
• W2893948512 hasRelatedWork W2333897269 @default.
• W2893948512 hasRelatedWork W2509762766 @default.
• W2893948512 hasRelatedWork W2530207093 @default.
• W2893948512 hasRelatedWork W2989981638 @default.
• W2893948512 hasRelatedWork W67104293 @default.
• W2893948512 hasVolume "4" @default.
• W2893948512 isParatext "false" @default.
• W2893948512 isRetracted "false" @default.
• W2893948512 magId "2893948512" @default.
• W2893948512 workType "article" @default.